NF2 and neoplasm: Based on differential drug synergy in NF2-deficient versus NF2-expressing cells, the stage of drug development, and compound performance in prior preclinical and clinical evaluations including pharmacology, response rate, toxicity, and availability, we selected and ranked the top three drug combinations for each NF2 tumor type.